Search research articles
Contact Us
Filters
Showing results (11-20 of 25) with videos related to
Page
of 3
Sort By:
American Journal of Cancer Research
|
August 14, 2015
Nek6 and Hif-1α cooperate with the cytoskeletal gateway of drug resistance to drive outcome in serous ovarian cancer
Marta De Donato, Mara Fanelli, Marisa Mariani, et al.
Oncotarget
|
July 3, 2015
Role and prognostic significance of the epithelial-mesenchymal transition factor ZEB2 in ovarian cancer
Silvia Prislei, Enrica Martinelli, Gian Franco Zannoni, et al.
Cancer Research
|
December 17, 2008
Molecular mechanisms of patupilone resistance
Simona Mozzetti, Raffaella Iantomasi, Ilaria De Maria, et al.
Plos One
|
December 9, 2014
Herpes virus microRNA expression and significance in serous ovarian cancer
Deep Pandya, Marisa Mariani, Mark McHugh, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 23, 2012
Gender influences the class III and V β-tubulin ability to predict poor outcome in colorectal cancer
Marisa Mariani, Gian Franco Zannoni, Stefano Sioletic, et al.
Journal of Cellular Physiology
|
April 27, 2011
Class III β-tubulin and the cytoskeletal gateway for drug resistance in ovarian cancer
Marta De Donato, Marisa Mariani, Lella Petrella, et al.
Oncotarget
|
June 23, 2014
HGF/c-Met axis drives cancer aggressiveness in the neo-adjuvant setting of ovarian cancer
Marisa Mariani, Mark McHugh, Marco Petrillo, et al.
European Journal of Medicinal Chemistry
|
August 2, 2014
GTP is an allosteric modulator of the interaction between the guanylate-binding protein 1 and the prosurvival kinase PIM1
Marco Persico, Lella Petrella, Nausicaa Orteca, et al.
Gene
|
March 26, 2014
Sox9 and Hif-2α regulate TUBB3 gene expression and affect ovarian cancer aggressiveness
Giuseppina Raspaglio, Marco Petrillo, Enrica Martinelli, et al.
Journal of Medicinal Chemistry
|
September 12, 2014
Identification of the first inhibitor of the GBP1:PIM1 interaction. Implications for the development of a new class of anticancer agents against paclitaxel resistant cancer cells
Mirko Andreoli, Marco Persico, Ajay Kumar, et al.
Page
of 3
Search research articles
Search
Showing results (11-20 of 25) with videos related to
Sort By:
Page
of 3
American Journal of Cancer Research
|
August 14, 2015
Nek6 and Hif-1α cooperate with the cytoskeletal gateway of drug resistance to drive outcome in serous ovarian cancer
Marta De Donato, Mara Fanelli, Marisa Mariani, et al.
Oncotarget
|
July 3, 2015
Role and prognostic significance of the epithelial-mesenchymal transition factor ZEB2 in ovarian cancer
Silvia Prislei, Enrica Martinelli, Gian Franco Zannoni, et al.
Cancer Research
|
December 17, 2008
Molecular mechanisms of patupilone resistance
Simona Mozzetti, Raffaella Iantomasi, Ilaria De Maria, et al.
Plos One
|
December 9, 2014
Herpes virus microRNA expression and significance in serous ovarian cancer
Deep Pandya, Marisa Mariani, Mark McHugh, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 23, 2012
Gender influences the class III and V β-tubulin ability to predict poor outcome in colorectal cancer
Marisa Mariani, Gian Franco Zannoni, Stefano Sioletic, et al.
Journal of Cellular Physiology
|
April 27, 2011
Class III β-tubulin and the cytoskeletal gateway for drug resistance in ovarian cancer
Marta De Donato, Marisa Mariani, Lella Petrella, et al.
Oncotarget
|
June 23, 2014
HGF/c-Met axis drives cancer aggressiveness in the neo-adjuvant setting of ovarian cancer
Marisa Mariani, Mark McHugh, Marco Petrillo, et al.
European Journal of Medicinal Chemistry
|
August 2, 2014
GTP is an allosteric modulator of the interaction between the guanylate-binding protein 1 and the prosurvival kinase PIM1
Marco Persico, Lella Petrella, Nausicaa Orteca, et al.
Gene
|
March 26, 2014
Sox9 and Hif-2α regulate TUBB3 gene expression and affect ovarian cancer aggressiveness
Giuseppina Raspaglio, Marco Petrillo, Enrica Martinelli, et al.
Journal of Medicinal Chemistry
|
September 12, 2014
Identification of the first inhibitor of the GBP1:PIM1 interaction. Implications for the development of a new class of anticancer agents against paclitaxel resistant cancer cells
Mirko Andreoli, Marco Persico, Ajay Kumar, et al.
Page
of 3